Q1 2024 EPS Estimates for Stoke Therapeutics, Inc. Lowered by Wedbush (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush decreased their Q1 2024 EPS estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, March 26th. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.61) per share for the quarter, down from their previous forecast of ($0.57). Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.65) EPS, Q4 2024 earnings at ($0.60) EPS, FY2024 earnings at ($2.48) EPS, FY2026 earnings at ($2.97) EPS, FY2027 earnings at ($1.53) EPS and FY2028 earnings at $1.39 EPS.

STOK has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday. Needham & Company LLC boosted their price objective on shares of Stoke Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday. Canaccord Genuity Group lifted their target price on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday. TD Cowen upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.63.

Stoke Therapeutics Trading Up 37.7 %

STOK opened at $14.17 on Thursday. The stock has a 50-day moving average of $5.88 and a 200-day moving average of $4.95. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.40.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total value of $48,000.00. Following the sale, the insider now owns 6,981 shares of the company’s stock, valued at approximately $33,508.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the sale, the insider now directly owns 6,981 shares of the company’s stock, valued at $33,508.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 11,150 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,615 shares of company stock worth $212,852. 12.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in Stoke Therapeutics by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after acquiring an additional 837 shares in the last quarter. American International Group Inc. lifted its stake in shares of Stoke Therapeutics by 10.9% in the 2nd quarter. American International Group Inc. now owns 10,506 shares of the company’s stock valued at $139,000 after purchasing an additional 1,029 shares during the period. Great West Life Assurance Co. Can lifted its stake in shares of Stoke Therapeutics by 46.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after purchasing an additional 1,078 shares during the period. Ensign Peak Advisors Inc acquired a new position in shares of Stoke Therapeutics during the 1st quarter worth about $25,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Stoke Therapeutics in the 1st quarter valued at about $27,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.